Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion




Patents and patent applications


Biosimilars under development

Interview with CEO Martin Åmark, October 2023

At Xbrane Biopharma

Press Releases

27 Feb 2024

Trading in unit rights and BTUs in Xbrane’s rights issue will commence on 29 February 2024

27 Feb 2024

Xbrane publishes prospectus in connection with the company’s partially guaranteed rights issue of approximately SEK 343 million

26 Feb 2024

Xbrane Biopharma releases Year-end Report 2023

22 Feb 2024

Announcement from Extra General Meeting in Xbrane Biopharma AB

21 Feb 2024

Invitation to presentation of Xbrane Biopharma’s Year-end report 2023 on February 26, 2024

05 Feb 2024

Xbrane sends shareholder letter in connection with the proposed rights issue

22 Jan 2024

Notice of Extra General Meeting in Xbrane Biopharma AB

22 Jan 2024

Xbrane announces a rights issue of units of approximately SEK 343 million

22 Dec 2023